Gene therapies can reduce treatment burden and costs for patients with blood disorders
Anew analysis found potential gene therapies for blood disorders like hemophilia, beta thalassemia, and sickle cell disease hold promise in dramatically reducing existing treatment burdens for patients, which could result in as much as $730,000 in savings to the health care system and increase a patient ’s income by as much as $9,500 in the year following treatment.
Source: The Catalyst - Category: Pharmaceuticals Authors: Katie Koziara Tags: Medicines in Development Personalized Medicine Source Type: news
More News: Gene Therapy | Genetics | Haemophilia | Health Management | Hemophilia | Pharmaceuticals | Sickle Cell Anemia